A phase I trial of TCN-PM in patients with solid tumors including gastroesophageal cancer carrying increased phosphorylated Akt (p-Akt) reported modest decreases in tumor p-AKT after TCN-PM monotherapy treatment (Garrett et al., 2011). The gene discussed is AKT1; the disease is neoplasm.